Anika Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Anika Therapeutics

27/07/2026 13:49

Anika Therapeutics Inc ANIK.OQ ANIK.O is expected to  show a rise in quarterly revenue when it reports  results on July 29 for the period ending June 30 2026
The Bedford Massachusetts-based  company is expected to report a 3.5% increase in revenue to $29.215 million from $28.22 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Anika Therapeutics Inc is for a loss of 8 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Anika Therapeutics Inc is $17.50, about 17.1% above its last closing price of $14.95
This summary was machine generated July 27 at 12:49 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)